Buchumschlag

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program☆

Background - Circulating tumor cells (CTCs) have been reported to predict clinical outcome in metastatic breast cancer (MBC). Biology of CTCs may differ from that of the primary tumor and HER2-positive CTCs are found in some patients with HER2-negative tumors. - Patients and methods - Patients with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Müller, Volkmar (VerfasserIn) , Banys-Paluchowski, M. (VerfasserIn) , Friedl, T. W. P. (VerfasserIn) , Fasching, P. A. (VerfasserIn) , Schneeweiss, Andreas (VerfasserIn) , Hartkopf, A. (VerfasserIn) , Wallwiener, D. (VerfasserIn) , Rack, B. (VerfasserIn) , Meier-Stiegen, F. (VerfasserIn) , Huober, J. (VerfasserIn) , Rübner, M. (VerfasserIn) , Hoffmann, O. (VerfasserIn) , Müller, L. (VerfasserIn) , Janni, W. (VerfasserIn) , Wimberger, P. (VerfasserIn) , Jäger, B. (VerfasserIn) , Pantel, K. (VerfasserIn) , Riethdorf, S. (VerfasserIn) , Harbeck, N. (VerfasserIn) , Fehm, T. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 25 November 2021
In: ESMO open
Year: 2021, Jahrgang: 6, Heft: 6, Pages: 1-8
ISSN:2059-7029
DOI:10.1016/j.esmoop.2021.100299
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.esmoop.2021.100299
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S2059702921002611
Volltext
Verfasserangaben:V. Müller, M. Banys-Paluchowski, T.W.P. Friedl, P.A. Fasching, A. Schneeweiss, A. Hartkopf, D. Wallwiener, B. Rack, F. Meier-Stiegen, J. Huober, M. Rübner, O. Hoffmann, L. Müller, W. Janni, P. Wimberger, B. Jäger, K. Pantel, S. Riethdorf, N. Harbeck & T. Fehm, on behalf of DETECT study group
Beschreibung
Zusammenfassung:Background - Circulating tumor cells (CTCs) have been reported to predict clinical outcome in metastatic breast cancer (MBC). Biology of CTCs may differ from that of the primary tumor and HER2-positive CTCs are found in some patients with HER2-negative tumors. - Patients and methods - Patients with HER2-negative MBC were screened for participation in DETECT III and IV trials before the initiation of a new line of therapy. Blood samples were analyzed using CELLSEARCH. CTCs were labeled with an anti-HER2 antibody and classified according to staining intensity (negative, weak, moderate, or strong staining). - Results - Screening blood samples were analyzed in 1933 patients with HER2-negative MBC. As many as 1217 out of the 1933 screened patients (63.0%) had ≥1 CTC per 7.5 ml blood; ≥5 CTCs were detected in 735 patients (38.0%; range 1-35 078 CTCs, median 8 CTCs). HER2 status of CTCs was assessed in 1159 CTC-positive patients; ≥1 CTC with strong HER2 staining was found in 174 (15.0%) patients. The proportion of CTCs with strong HER2 staining among all CTCs of an individual patient ranged between 0.06% and 100% (mean 15.8%). Patients with estrogen receptor (ER)- and progesterone receptor (PR)-positive tumors were more likely to harbor ≥1 CTC with strong HER2 staining. CTC status was significantly associated with overall survival (OS). Detection of ≥1 CTC with strong HER2 staining was associated with shorter OS [9.7 (7.1-12.3) versus 16.5 (14.9-18.1) months in patients with CTCs with negative-to-moderate HER2 staining only, P = 0.013]. In multivariate analysis, age, ER status, PR status, Eastern Cooperative Oncology Group performance status, therapy line, and CTC status independently predicted OS. - Conclusion - CTC detection in patients with HER2-negative disease is a strong prognostic factor. Presence of ≥1 CTC with strong HER2 staining was associated with shorter OS, supporting a biological role of HER2 expression on CTCs.
Beschreibung:Gesehen am 20.12.2022
Beschreibung:Online Resource
ISSN:2059-7029
DOI:10.1016/j.esmoop.2021.100299

Ähnliche Einträge